We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS (STE) Banks on Organic Growth, Competition Intense
Read MoreHide Full Article
On Aug 14, we issued an updated research report on Ohio-based STERIS plc (STE - Free Report) – a manufacturer and marketer of infection prevention, decontamination, microbial reduction along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #2 (Buy).
STERIS posted better-than-expected results in first-quarter fiscal 2018 with both earnings and revenues beating the Zacks Consensus Estimate. However, the year-over-year decline in revenues is dampening.
On a positive note, organic growth performance was strong across all segments. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance. Also, gross and operating margin expanded year over year. Recently, the company made a couple of organizational changes to serve customers in a better way. We expect this move to enhance the company’s cost structure as well. Over the last three months, the stock has gained 13.1%, which outperformed the 1.1% decline of the broader industry.
However, we note that the government and insurance companies’ consistent efforts to curb healthcare costs have been putting pressure on the stock for quite some time. We are also concerned about the current customer consolidation scenario which will continue to affect the company, unless checked immediately. The competitive landscape and weak cost reduction initiatives are other overhangs.
Edwards Lifesciences has a positive earnings surprise of 10.75% for the trailing four quarters. The stock has gained around 0.9% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 25.4% over the last three months.
Stryker has a long-term expected earnings growth rate of 10.0%. The stock has gained 5.9% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
STERIS (STE) Banks on Organic Growth, Competition Intense
On Aug 14, we issued an updated research report on Ohio-based STERIS plc (STE - Free Report) – a manufacturer and marketer of infection prevention, decontamination, microbial reduction along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #2 (Buy).
STERIS posted better-than-expected results in first-quarter fiscal 2018 with both earnings and revenues beating the Zacks Consensus Estimate. However, the year-over-year decline in revenues is dampening.
On a positive note, organic growth performance was strong across all segments. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance. Also, gross and operating margin expanded year over year. Recently, the company made a couple of organizational changes to serve customers in a better way. We expect this move to enhance the company’s cost structure as well. Over the last three months, the stock has gained 13.1%, which outperformed the 1.1% decline of the broader industry.
However, we note that the government and insurance companies’ consistent efforts to curb healthcare costs have been putting pressure on the stock for quite some time. We are also concerned about the current customer consolidation scenario which will continue to affect the company, unless checked immediately. The competitive landscape and weak cost reduction initiatives are other overhangs.
Other Key Picks
Other top-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Stryker Corporation (SYK - Free Report) and Align Technology, Inc. (ALGN - Free Report) . Edwards Lifesciences and Align Technology sport a Zacks Rank #1 (Strong Buy), while Stryker carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a positive earnings surprise of 10.75% for the trailing four quarters. The stock has gained around 0.9% over the last three months.
Align Technology has a long-term expected earnings growth rate of 26.6%. The stock has rallied roughly 25.4% over the last three months.
Stryker has a long-term expected earnings growth rate of 10.0%. The stock has gained 5.9% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>